Context Therapeutics (NASDAQ:CNTX) Stock Rating Upgraded by Lifesci Capital

Context Therapeutics (NASDAQ:CNTX) was upgraded by equities research analysts at Lifesci Capital to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

Several other research firms have also issued reports on CNTX. Wall Street Zen raised Context Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, February 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Context Therapeutics in a research note on Wednesday, January 21st. HC Wainwright upped their target price on shares of Context Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. D. Boral Capital reiterated a “buy” rating and set a $9.00 price target on shares of Context Therapeutics in a report on Thursday, November 6th. Finally, JonesTrading assumed coverage on shares of Context Therapeutics in a research report on Monday, December 22nd. They set a “buy” rating and a $7.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Context Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.00.

Context Therapeutics Trading Up 8.8%

Shares of NASDAQ:CNTX opened at $2.48 on Monday. The stock has a fifty day simple moving average of $1.83 and a two-hundred day simple moving average of $1.32. Context Therapeutics has a 12-month low of $0.49 and a 12-month high of $2.85. The stock has a market capitalization of $227.86 million, a price-to-earnings ratio of -10.33 and a beta of 1.94.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in shares of Context Therapeutics by 4.0% in the 3rd quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after purchasing an additional 134,449 shares in the last quarter. Marshall Wace LLP grew its position in shares of Context Therapeutics by 7,153.7% during the fourth quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock worth $3,812,000 after purchasing an additional 2,557,448 shares in the last quarter. Millennium Management LLC bought a new stake in shares of Context Therapeutics during the fourth quarter valued at approximately $3,824,000. Clear Harbor Asset Management LLC increased its holdings in Context Therapeutics by 60.5% in the 3rd quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock valued at $90,000 after acquiring an additional 35,000 shares during the last quarter. Finally, Blue Owl Capital Holdings LP lifted its stake in Context Therapeutics by 0.3% in the 4th quarter. Blue Owl Capital Holdings LP now owns 7,432,906 shares of the company’s stock worth $10,926,000 after purchasing an additional 25,000 shares in the last quarter. Institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.